These findings are internally consistent across multiple in vivo assays and single-cell analyses, although they also reveal a nuance: tumor-intrinsic YTHDF1 loss can increase PD-L1 in vivo while still enhancing T-cell–mediated control, implying that improved antigen presentation and T-cell priming can dominate over incremental checkpoint upregulation (88). This evidence concerns the gene CD274 and neoplasm.